StockData
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc. (TYRA) shareholders

TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$19.57−0.17 (-0.86%)

Close on Nov 17, 2026Market cap $1.17BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
69M of 60M shares
Institutional holders
170
33 new, 25 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
1 buys · 10 sales
Net sold $8.46M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (19.90%), Rajeev Shah (19.90%) and 1 more
14,130,49219.90%13D (active) amendmentSep 15, 2026
Rajeev Shah
Joint filing with RA Capital Management, L.P. (22.40%), Peter Kolchinsky (22.40%) and 1 more
11,899,78822.40%13D (active) amendmentJun 4, 2025
Abigail P. Johnson
Joint filing with FMR LLC (14.40%)
7,747,64814.40%13G (passive)Mar 31, 2026
Lampert Mark N
Joint filing with Bvf Partners L P/Il (6.10%), Bvf Inc/Il (6.10%) and 1 more
4,215,8866.10%13G (passive)Sep 14, 2026
Bvf Inc/Il
Joint filing with Bvf Partners L P/Il (7.80%), Lampert Mark N (7.80%) and 1 more
3,944,1947.80%13G (passive) amendmentDec 31, 2024
Janus Henderson Group PLC3,890,5897.20%13G (passive) amendmentMar 31, 2026
Saito Edric C.
Joint filing with Wehrly, Mark C. (6.60%), Dapice Joshua J. (6.60%) and 13 more
3,580,8186.60%13G (passive) amendmentMar 31, 2026
Nextech VI GP S.a. r.l.
Joint filing with Nextech VI Oncology SCSp (6.00%), Ian Charoub (6.00%) and 2 more
3,553,5856.00%13G (passive) amendmentJun 30, 2026
Senai Asefaw, M.D.
Joint filing with Paradigm BioCapital Advisors LP (5.80%), Paradigm BioCapital Advisors GP LLC (5.80%) and 1 more
3,473,4535.80%13G (passive)Sep 10, 2026
Commodore Capital LP
Joint filing with Commodore Capital Master LP (6.30%), Robert Egen Atkinson (6.30%) and 1 more
3,375,0006.30%13G (passive) amendmentSep 30, 2025
Dapice Joshua J.
Joint filing with Wehrly, Mark C. (5.60%), Dreyfuss, Philip D. (5.60%) and 13 more
2,984,8185.60%13G (passive)Feb 12, 2026
Canaan XI L.P.
Joint filing with Canaan Partners XI LLC (5.50%)
2,930,4445.50%13G (passive) amendmentDec 31, 2025
TCG Crossover GP I, LLC
Joint filing with TCG Crossover Fund I, L.P. (5.70%), Chen Yu (5.70%)
2,898,1035.70%13G (passive)Feb 27, 2025
Aaron I. Davis2,548,9055.00%13D (active) amendmentDec 4, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of TYRAValueChange% of portfolio
Ra Capital Management, L.P.12,198,62520.44%$389.62M–3.39%
FMR LLC8,920,51314.95%$284.92M+1,172,8650.01%
Jupiter Topco LLC4,352,4487.29%$139.16MNew0.06%
Alta Partners Management Company, L.P.3,823,4256.41%$122.12M–95.92%
Nextech Invest, Ltd.3,553,5855.95%$113.50M−502,2765.39%
TCG Crossover Management, LLC3,248,9805.44%$103.77M–2.49%
BlackRock, Inc.3,031,9725.08%$96.84M+814,0430.00%
Price T Rowe Associates Inc /Md/2,782,5674.66%$88.88M+1,796,5060.01%
State Street Corp2,140,3683.59%$68.36M+924,2900.00%
Commodore Capital LP1,875,0003.14%$59.89M−600,0003.57%
Paradigm Biocapital Advisors LP1,828,6073.06%$58.41M−226,3841.09%
Vanguard Capital Management LLC1,508,4472.53%$48.18M+382,4770.00%
Bvf Inc/Il1,476,1962.47%$47.15M−500,0001.21%
5AM Venture Management, LLC1,029,2981.72%$32.88M–11.42%
Deerfield Management Company, L.P. (Series C)1,017,0001.70%$32.48M+468,0000.34%
Hood River Capital Management LLC1,016,7751.70%$32.48MNew0.24%
Geode Capital Management, LLC970,7341.63%$31.01M+312,2520.00%
Caligan Partners LP806,9861.35%$25.78M−469,9821.21%
Canaan Partners XI LLC750,0001.26%$23.96M–18.82%
Siren, L.L.C.725,0001.21%$23.16MNew0.47%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202617069M100.0%33 / 7344 / 2517M10M
Q1 202616466M100.0%46 / 6035 / 1422M11M
Q4 202513357M95.2%29 / 4338 / 106M4M
Q3 202511656M93.4%9 / 4137 / 142M3M
Q2 202512157M94.9%18 / 6220 / 147M4M
Q1 202511754M89.8%22 / 4231 / 1613M4M
Q4 202411349M81.5%36 / 3425 / 1812M11M
Q3 20249547M79.5%25 / 2920 / 84M2M
Q2 20247947M79.1%18 / 3017 / 163M3M
Q1 20247747M79.3%22 / 2615 / 712M1M
Q4 20236236M60.7%9 / 2112 / 61M2M
Q3 20235936M61.1%4 / 1616 / 41M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

187 funds held TYRA in Q2 2026, 30% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of TYRAValue% of fundAs of
Fidelity OTC Portfolio3,295,4465.52%$105.06M0.24%Jul 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,392,3762.33%$44.47M0.41%Jun 30, 2026
Vanguard Total Stock Market Index Fund1,135,4721.90%$36.27M0.00%Jun 30, 2026
iShares Russell 2000 ETF944,2011.58%$30.16M0.04%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.793,1401.33%$25.33M0.17%Jun 30, 2026
Fidelity Advisor Equity Growth Fund678,6001.14%$22.67M0.17%May 31, 2026
VIP Growth Portfolio630,8001.06%$20.15M0.16%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund558,5000.94%$17.84M0.18%Jun 30, 2026
Hood River Small-Cap Growth Fund492,2170.82%$15.72M0.24%Jun 30, 2026
Fidelity Small Cap Index Fund402,2310.67%$12.82M0.04%Jul 31, 2026
Fidelity Stock Selector Small Cap Fund389,8000.65%$12.43M0.17%Jul 31, 2026
Fidelity Small Cap Growth Fund374,5400.63%$11.94M0.14%Jul 31, 2026
Janus Henderson Triton Fund357,1070.60%$11.41M0.19%Jun 30, 2026
Fidelity Advisor Biotechnology Fund354,2000.59%$11.29M0.51%Jul 31, 2026
Fidelity Growth Discovery Fund341,7000.57%$10.91M0.16%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Todd HarrisPresident and CEO, Director1,438,4952.41%Sep 17, 2026
Yuliya RuebVice President, Finance (PAO)11,2580.02%Sep 17, 2026
Alan FuhrmanChief Financial Officer37,1150.06%Sep 17, 2026
Bhavesh AsharChief Operating Officer15,0130.03%May 7, 2026
Douglas J. WarnerChief Medical Officer25,0000.04%May 7, 2026
Daniel BensenChief Discovery Officer146,9810.25%Feb 13, 2026
Capital Healthcare Fund LP RADirector, 10% owner10,096,00416.92%Sep 17, 2026
Rajeev M. ShahDirector, 10% owner8,477,27514.21%Sep 17, 2026
Peter KolchinskyDirector, 10% owner9,909,15416.60%Sep 17, 2026
RA Capital Nexus Fund, L.P.Director4,047,1206.78%Sep 17, 2026
Ra Capital Management, L.P.Director, 10% owner10,259,29117.19%Sep 17, 2026
Rehan VerjeeDirector9720.00%Sep 11, 2026
Susan MoranDirector0–Jun 1, 2026
Adele M. GulfoDirector4,0000.01%Jun 1, 2026
Jake SimsonDirector––Jun 1, 2026
Stephen Michael RothenbergDirector0–Jun 1, 2026
Robert J. MoreDirector3,823,4256.41%Jun 1, 2026
Habib J. DableDirector0–Apr 20, 2026
Gilla KaplanDirector28,2310.05%Mar 27, 2026
Nina S. KjellsonDirector4,144,5906.95%Feb 7, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Yuliya Rueb
Vice President, Finance (PAO)
Sep 15, 2026Award+2,925$9.13$26.71K11,258
Todd Harris
President and CEO, Director
Sep 15, 2026Award+864$9.13$7.89K1,438,495
Alan Fuhrman
Chief Financial Officer
Sep 15, 2026Award+951$9.13$8.68K37,115
Rehan Verjee
Director
Sep 9, 2026Buy+971.89$20.58$20.00K972
Yuliya Rueb
Vice President, Finance (PAO)
May 5, 2026Award+8,333––43,354
Todd Harris
President and CEO, Director
May 5, 2026Award+79,000––1,437,631
Alan Fuhrman
Chief Financial Officer
May 5, 2026Award+20,000––36,164
Douglas J. Warner
Chief Medical Officer
May 5, 2026Award+25,000––25,000
Bhavesh Ashar
Chief Operating Officer
May 5, 2026Award+15,013––15,013
Gilla Kaplan
Director
Mar 26, 2026Returned to company−53,172$37.75$2.01M28,231
Gilla Kaplan
Director
Mar 26, 2026Option exercise−53,172$2.25$119.64K81,403
Gilla Kaplan
Director
Mar 25, 2026Option exercise+14,295$2.25$32.16K42,526
Gilla Kaplan
Director
Mar 25, 2026Sale−14,295$36.97$528.49K28,231
Alan Fuhrman
Chief Financial Officer
Mar 13, 2026Award+1,376$9.13$12.56K16,164
Todd Harris
President and CEO, Director
Mar 13, 2026Award+1,463$9.13$13.36K1,358,631
Daniel Bensen
Chief Discovery Officer
Feb 12, 2026Sale(10b5-1 plan)−5,872$33.37$195.95K146,981
Daniel Bensen
Chief Discovery Officer
Feb 12, 2026Sale(10b5-1 plan)−2,128$31.50$67.03K152,853
Daniel Bensen
Chief Discovery Officer
Jan 12, 2026Sale(10b5-1 plan)−1,017$29.08$29.57K154,981
Daniel Bensen
Chief Discovery Officer
Jan 12, 2026Sale(10b5-1 plan)−6,983$28.44$198.60K155,998
Robert J. More
Director
Dec 19, 2025Sale(10b5-1 plan)−10,000$25.00$250.00K3,823,425
Daniel Bensen
Chief Discovery Officer
Dec 12, 2025Sale(10b5-1 plan)−8,000$22.64$181.12K162,981
Robert J. More
Director
Nov 21, 2025Sale(10b5-1 plan)−246,871$20.25$5.00M3,833,425
Daniel Bensen
Chief Operating Officer
Nov 19, 2025Sale(10b5-1 plan)−49,956$16.32$815.28K170,981
Daniel Bensen
Chief Operating Officer
Nov 18, 2025Sale(10b5-1 plan)−75,633$16.07$1.22M220,937
Daniel Bensen
Chief Operating Officer
Nov 17, 2025Sale(10b5-1 plan)−18,572$16.11$299.19K298,070
Daniel Bensen
Chief Operating Officer
Nov 17, 2025Sale(10b5-1 plan)−1,500$17.07$25.61K296,570
Daniel Bensen
Chief Operating Officer
Nov 14, 2025Sale(10b5-1 plan)−110,228$16.02$1.77M316,642
Daniel Bensen
Chief Operating Officer
Nov 13, 2025Sale(10b5-1 plan)−1,111$16.00$17.78K426,870
Alan Fuhrman
Chief Financial Officer
Sep 15, 2025Award+701$9.13$6.40K14,788
Gilla Kaplan
Director
Jun 18, 2025Sale−9,568$9.78$93.58K28,231
Gilla Kaplan
Director
Jun 17, 2025Sale−10$10.35$10437,799
Gilla Kaplan
Director
Jun 16, 2025Sale−6,814$10.38$70.73K37,809
Ra Capital Management, L.P.
Director, 10% owner
Jun 16, 2025Buy+11,813$10.13$119.67K10,259,291
Gilla Kaplan
Director
Jun 13, 2025Sale−15,000$10.31$154.65K44,623
Ra Capital Management, L.P.
Director, 10% owner
Jun 13, 2025Buy+120,167$10.20$1.23M10,247,478
Gilla Kaplan
Director
Jun 12, 2025Sale−30,000$10.31$309.30K59,623
Ra Capital Management, L.P.
Director, 10% owner
Jun 12, 2025Buy+31,307$10.20$319.33K10,127,311
Capital Healthcare Fund LP RA
Director, 10% owner
Jun 9, 2025Buy+186,850$10.19$1.90M10,096,004
Peter Kolchinsky
Director, 10% owner
Jun 5, 2025Buy+213,334$10.04$2.14M9,909,154
Peter Kolchinsky
Director, 10% owner
Jun 4, 2025Buy+997,864$9.63$9.61M9,695,820
Todd Harris
President and CEO, Director
Mar 14, 2025Award+1,241$9.78$12.14K1,357,168
Alan Fuhrman
Chief Financial Officer
Mar 14, 2025Award+1,238$9.78$12.11K14,087
Nina S. Kjellson
Director
Feb 5, 2025Sale−3,511$13.76$48.31K443,885
Nina S. Kjellson
Director
Feb 5, 2025Sale−1,890$13.76$26.01K3,700,705
Nina S. Kjellson
Director
Jan 23, 2025Sale−4,825$16.26$78.45K3,702,595
Nina S. Kjellson
Director
Jan 21, 2025Sale−3,993$16.36$65.33K3,707,420
Nina S. Kjellson
Director
Jan 17, 2025Sale−12,808$16.40$210.05K3,711,413
Nina S. Kjellson
Director
Jan 17, 2025Sale−461$16.40$7.56K447,396
Nina S. Kjellson
Director
Jan 16, 2025Sale−835$16.29$13.60K447,857
Nina S. Kjellson
Director
Jan 16, 2025Sale−6,944$16.29$113.12K3,724,221
Nina S. Kjellson
Director
Nov 25, 2024Sale−566$16.84$9.53K448,692
Nina S. Kjellson
Director
Nov 25, 2024Sale−4,706$16.84$79.25K3,731,165
Capital Healthcare Fund LP RA
Director, 10% owner
Nov 8, 2024Buy+1,220,681$16.25$19.84M8,697,956
Nina S. Kjellson
Director
Nov 7, 2024Sale−19,720$17.32$341.55K3,735,871
Nina S. Kjellson
Director
Nov 7, 2024Sale−2,371$17.32$41.07K449,258
Nina S. Kjellson
Director
Nov 6, 2024Sale−5,635$17.18$96.81K451,629
Nina S. Kjellson
Director
Nov 6, 2024Sale−46,856$17.18$804.99K3,755,591
Nina S. Kjellson
Director
Nov 5, 2024Sale−1,126$16.77$18.88K457,264
Nina S. Kjellson
Director
Nov 5, 2024Sale−9,367$16.77$157.08K3,802,447
Nina S. Kjellson
Director
Nov 4, 2024Sale−116$17.01$1.97K458,390

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
36.28%
10M shares short
Days to cover
15.3
At 1M shares a day
Change since last report
+4.3%
From 9M shares
Short volume, 20 days
69.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tyra Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,567 shares on Sep 10, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Nextech Vi Oncology Scsp
Shareholder
Jun 26, 2026308,379$9.54MJun 26, 2026Private Placement
Nextech Vi Oncology Scsp
Shareholder
Jun 1, 2026300,000$10.02MJun 1, 2026Private Placement
Daniel Bensen
Officer
May 12, 20268,000$274.00KMay 12, 2026Founders shares
Daniel Bensen
Officer
Apr 13, 20268,000$285.00KApr 13, 2026Founders shares
Gilla Kaplan
Director
Mar 26, 202653,172$2.01MMar 26, 2026Stock Option Exercise
Gilla Kaplan
Director
Mar 25, 202614,295$528.51KMar 25, 2026Stock Option Exercise
Daniel Bensen
Officer
Mar 12, 20268,000$283.00KMar 12, 2026Founders shares
Daniel Bensen
Officer
Feb 12, 20268,000$262.00KFeb 12, 2026Founders shares
Daniel Bensen
Officer
Jan 12, 20268,000$232.00KJan 12, 2026Founders shares
Daniel Bensen
Officer
Dec 12, 20258,000$180.00KDec 12, 2025Founders shares
Alta Partners NextGen Fund II, L.P.
Affiliate
Nov 21, 2025256,871$5.39MNov 21, 2025Private Placement
Daniel Bensen
Officer
Nov 18, 2025124,589$2.00MNov 18, 2025Founders shares
Daniel Bensen
Officer
Nov 17, 202520,072$320.00KNov 17, 2025Founders shares
Daniel Bensen
Officer
Nov 14, 202586,339$1.38MNov 14, 2025Founders shares
Daniel Bensen
Officer
Nov 13, 202525,000$400.00KNov 13, 2025Founders shares

See a number that looks wrong?